CASI PHARMACEUTICALS, INC. Debt and Equity Securities, Unrealized Gain (Loss)
CASI PHARMACEUTICALS, INC. (CASIF) reported Debt and Equity Securities, Unrealized Gain (Loss) of $35.00 thousand for the 12-month period ending 2023-12-31, per its 20-F filed 2025-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss · last filed 2025-03-31
| Period end | Debt and Equity Securities, Unrealized Gain (Loss) 12 month |
|---|---|
| 2023-12-31 | $35.00K 20-F · filed 2025-03-31 |
| 2022-12-31 | $20.00K 20-F · filed 2024-03-28 |
| 2021-12-31 | $7.04M 20-F · filed 2023-04-26 |